-
ALSO READ
Coronavirus vaccine update: Bharat Biotech starts human trial at PGI-Rohtak
India's role in production of Covid-19 vaccine critical: Bill Gates
Phase II clinical trials of Bharat Biotech's Covid-19 vaccine from Sept 7
When will India finally have access to coronavirus vaccine?
Potential Covid-19 vaccines not affected by recent mutations: Report
-
With COVID-19 vaccines of Serum Institue of India and Bharat Biotech being granted permission for restricted use in an emergency situation, Union Minister of State for Health and Family Welfare Ashwini Kumar Choubey on Sunday stated that India will become corona-free.
"DCGI has approved the emergency use of Covaxin and Covishield. This is a major achievement in the successful war against Coronavirus under Prime Minister Shri @narendramodi's leadership," Choubey said in a tweet.
The Minister further added that India will become corona free. He also congratulated countrymen including scientists and health workers.
Earlier today, COVID-19 vaccines of Serum Institue of India and Bharat Biotech were granted permission for restricted use in an emergency situation, said Drugs Controller General of India (DCGI).
"After adequate examination, Central Drugs Standard Control Organisation (CDSCO) has decided to accept the recommendations of the Expert Committee and accordingly, vaccines of M/s Serum and M/s Bharat Biotech are being approved for restricted use in emergency situation and permission is being granted to M/s Cadila Healthcare for the conduct of the Phase III clinical trial," said VG Somani, DCGI, during a media briefing today.
Choubey on December 28 informed that he has tested positive for Covid-19. Choubey said that he is currently in home isolation on the advice of doctors and his health is fine.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU